- Published on
JAKOB-CREUTZFELDT DISEASE
ESSENTIAL DESCRIPTION
The neurodegenerative diseases known as transmissible spongiform encephalopathies affect both humans and animals and are chronic, progressive, and always deadly.
Sheep illness (also known as scrapie) and cow disease (also known as bovine spongiform encephalopathy, or BSE) are examples of animal-transmissible spongiform encephalopathies.
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Kuru (the first prion illness identified from Papua New Guinea), and deadly familial insomnia are examples of human-transmissible spongiform encephalopathies.
The most prevalent of the prion illnesses, CJD is typified by spastic dysarthria, tremor, muscle atrophy, and progressive dementia. There are several ways that CJD can manifest, including iatrogenic, familial, sporadic, and variant. The most prevalent type is sporadic.
• The only known prion disease that is transmitted from animals (BSE) to humans is variant CJD (vCJD), which was initially identified in 1996 after an outbreak that was concentrated in the United Kingdom.
• Three vCJD cases have been reported in the United States to date.
• A novel prion disease known as "proteinase-sensitive prionopathy" was identified in a group of 11 patients in 2008 and seems to run in families.
The incidence of epidemiology
• Of all spongiform encephalopathies, 85% are sporadic CJD (sCJD).
• The mean age of those with sCJD is between 50 and 60 years old, and the frequency is about 1 case per million.
• Although family cases with an autosomal dominant pattern of inheritance, like Gerstmann-Straussler-Scheinker syndrome, have been reported, the majority of cases are sporadic.
• There have been more reports of familial CJD in North Africa, the Middle East, Italy, and Slovakia.
• After corneal transplants, dural grafts, or incorrectly decontaminated neurosurgical tools and stereotactic intracerebral depth electrodes, the disease has spread.
• About 50 instances of panhypopituitarism patients receiving further cadaveric human growth hormone therapy have been documented, and in
individuals who were treated for infertility with cadaveric human gonadotropins.
RISK ELEMENTS
There is a weak association with previous exposure to farms.
Genetics Spongiform encephalopathies have been associated with certain mutations or polymorphisms in the prion gene, PRNP.
GENERAL PREVENTION: It is generally agreed that there is currently little chance of spongiform encephalopathies spreading in the United States due to the following factors:
There are sufficient laws in place to stop spongiform encephalopathies from entering the US from outside sources.
There are sufficient laws in place to stop undiscovered BSE cases from uncheckedly spreading throughout the US cattle population. There are also sufficient preventive guidelines in place to stop high-risk bovine components from contaminating goods meant for human consumption.
Pathophysiology
accumulation of aberrant host cell protein forms associated with the prion gene product, PRNP, in neural tissue.
Ethiology
Spongiform changes (small, round vacuoles) within the neuropil, neuronal loss, hypertrophy, glial cell proliferation, and the lack of significant inflammation or white matter involvement are the pathological hallmarks of CJD. The pathological changes are most severe in the cortex, but they are also frequently noticeable in the cerebellum, thalamus, and basal ganglia.
• The pathognomonic identification of prion illnesses is the presence of prion rods or plaques on electron micrographs of prepared brain material.
History of Diagnosis
• Kuru, the most well-known prion disease, is characterized by tremors (the word "kuru" means "shivering"), ataxia, and dementia.
• Up to 50 years may pass before the condition manifests itself.
• The majority of CJD patients experience myoclonus, pyramidal tract dysfunction, and rapidly advancing dementia early in the disease.
• Cognitive slowness, concentration issues, poor judgment, and memory loss are all signs of mental disability.
• Visual or other kinds of hallucinations may coexist with mood swings and emotional instability. • Cortical, subcortical, cerebellar, and spinal cord abnormalities can occur in nearly any combination. A more than 90% of patients develop myoclonus. Other motor symptoms and indicators may include choreoathetosis, clumsiness, and tremor.
• Approximately two-thirds of patients experience a parkinsonian extrapyramidal condition as the illness worsens, with
stiffness and hypokinesia. About half of patients experience extensor plantar reactions, hyperreflexia, and spasticity.
• In prion disease forms such fatal familial insomnia, autonomic (hyperthermia, hypertension, tachycardia) and endocrine (hypercortisol, growth hormone) problems may be observed.
• Patients with vCJD range in age from 19 to 41 years and have a progressive condition that leads to death between 7–23 months after beginning. • New cases of CJD have recently been reported in some European nations (mostly the United Kingdom) as a result of BSE transmission. Ataxia and early, noticeable behavioral abnormalities are among the clinical characteristics. Most people develop progressive dementia and myoclonus as later symptoms.
MEDICAL EXAMINATION
• Cognitive decline is prevalent and includes behavioral disorders, dementia, memory loss, and sleeplessness.
• More than 90% of patients have myoclonus.
• There may be cerebellar symptoms like ataxia and nystagmus.
• Up to 80% of patients may experience spasticity, hyperreflexia, and a positive Babinski sign.
Tests for Diagnosis and Interpretation Lab
• Only a brain histology investigation may provide a definitive diagnosis for all types of CJD.
• A comprehensive search for alternative processes should be initiated if cerebrospinal fluid (CSF) pleocytosis is atypical.
The sensitivity and specificity of 14-3-3, an aberrant protein, range from 60% to 90%, however it has been connected to CJD.
• Herpes, Alzheimer's disease, vascular dementia, and paraneoplastic syndromes are among the other illnesses that can potentially result in 14-3-3 increases.
• There is no doubt that mutations in the PRNP gene are linked to family occurrences of CJD, according to recent molecular genetic research. Variations in the disease's clinical phenotype within specific familial clusters may be related to a number of mutations that have been identified. Point mutations at codons 178, 200, and 210 are among them. Several CJD families also have octrepeat insertion in the PRNP gene.
• The brain-specific S 100 protein's median serum concentration is greater in CJD patients than in controls.
• The normal periodic EEG pattern typically linked to CJD is absent in vCJD.
Laboratory testing are useful in ruling out alternative causes of fast developing dementia. Prion protein plaques are widely dispersed throughout the cerebrum and cerebellum.
• Although the protein level may be slightly higher, the CSF is usually unremarkable.
• A quick diagnostic method called extraneural prion protein testing is being developed.
Imagining
• The amount of tissue loss observed on CT and MRI typically appears to be out of proportion to the severity of clinical dementia. Areas of elevated T2 signal intensity in the striatum have been seen on MRI in certain cases.
• Single-photon emission computed tomography (SPECT) examination of vCJD illness revealed decreased brain cortical perfusion.
Diagnostic Techniques and Other
• In some types, such sCJD, where sensitivity is 64% and specificity is 91%, the EEG can be a helpful diagnostic tool.
• Bilaterally synchronized sharp-wave complexes that occur at intervals of 0.5 to 2.5 will alternate with a generalized slow background to form a predicted pattern of CJD.
s and extending for 100–600 ms. • This typical EEG pattern is present in roughly 60–95% of patients, albeit it could not be seen at an early or advanced stage of the illness.
• Sharp-wave complexes may not be evident in Kuru, fatal familial insomnia, variant, or familial CJD.
Pathological Results
Small vacuoles occur inside the neuropil, giving it the distinctive spongiform look; multicentric plaques with spicules (cerebellum, mid-brain, and cerebrum) that stain for aberrant prion gene protein products, PrPSc, are PAS-positive.
DISTINCTIVE DIAGNOSIS
Alzheimer's disease, frontotemporal dementia, Lewy body dementia, alcoholism, HIV, tubercular meningitis, neurosyphilis, Whipple's disease, progressive multifocal leukoencephalopathy, lymphoma, amyloid angiopathy, metabolic abnormalities, and autoimmune disorders are among the many conditions that can also exhibit myoclonus and dementia symptoms.
MEDICATION FOR TREATMENT
• There is no specific treatment for CJD, and it is always deadly.
• In a few anecdotal case reports, amantadine has been shown to halt the advancement of the disease; however, the effects have not been repeatable.
• Other medications, including PrPSc inhibitors (chlorpromazine) and cytoprotective medicines (flupirtine), have been explored with little to no success in survival.
• Research is being done on molecular targeting and immunotherapy.
OTHER PROCEDURES AND SURGERY
For tissue diagnosis, neurosurgical services must be consulted. The high suspicion of prion disease should be communicated to all services, including pathology.
Continuing Care Follow-Up Suggestions
Sequential examinations conducted at biweekly or monthly intervals may reveal ventricular enlargement and quickly increasing brain tissue loss in certain patients.
Since there are now no treatments for PROGNOSIS disease, it is typically fatal.
ESSENTIAL DESCRIPTION
The neurodegenerative diseases known as transmissible spongiform encephalopathies affect both humans and animals and are chronic, progressive, and always deadly.
Sheep illness (also known as scrapie) and cow disease (also known as bovine spongiform encephalopathy, or BSE) are examples of animal-transmissible spongiform encephalopathies.
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Kuru (the first prion illness identified from Papua New Guinea), and deadly familial insomnia are examples of human-transmissible spongiform encephalopathies.
The most prevalent of the prion illnesses, CJD is typified by spastic dysarthria, tremor, muscle atrophy, and progressive dementia. There are several ways that CJD can manifest, including iatrogenic, familial, sporadic, and variant. The most prevalent type is sporadic.
• The only known prion disease that is transmitted from animals (BSE) to humans is variant CJD (vCJD), which was initially identified in 1996 after an outbreak that was concentrated in the United Kingdom.
• Three vCJD cases have been reported in the United States to date.
• A novel prion disease known as "proteinase-sensitive prionopathy" was identified in a group of 11 patients in 2008 and seems to run in families.
The incidence of epidemiology
• Of all spongiform encephalopathies, 85% are sporadic CJD (sCJD).
• The mean age of those with sCJD is between 50 and 60 years old, and the frequency is about 1 case per million.
• Although family cases with an autosomal dominant pattern of inheritance, like Gerstmann-Straussler-Scheinker syndrome, have been reported, the majority of cases are sporadic.
• There have been more reports of familial CJD in North Africa, the Middle East, Italy, and Slovakia.
• After corneal transplants, dural grafts, or incorrectly decontaminated neurosurgical tools and stereotactic intracerebral depth electrodes, the disease has spread.
• About 50 instances of panhypopituitarism patients receiving further cadaveric human growth hormone therapy have been documented, and in
individuals who were treated for infertility with cadaveric human gonadotropins.
RISK ELEMENTS
There is a weak association with previous exposure to farms.
Genetics Spongiform encephalopathies have been associated with certain mutations or polymorphisms in the prion gene, PRNP.
GENERAL PREVENTION: It is generally agreed that there is currently little chance of spongiform encephalopathies spreading in the United States due to the following factors:
There are sufficient laws in place to stop spongiform encephalopathies from entering the US from outside sources.
There are sufficient laws in place to stop undiscovered BSE cases from uncheckedly spreading throughout the US cattle population. There are also sufficient preventive guidelines in place to stop high-risk bovine components from contaminating goods meant for human consumption.
Pathophysiology
accumulation of aberrant host cell protein forms associated with the prion gene product, PRNP, in neural tissue.
Ethiology
Spongiform changes (small, round vacuoles) within the neuropil, neuronal loss, hypertrophy, glial cell proliferation, and the lack of significant inflammation or white matter involvement are the pathological hallmarks of CJD. The pathological changes are most severe in the cortex, but they are also frequently noticeable in the cerebellum, thalamus, and basal ganglia.
• The pathognomonic identification of prion illnesses is the presence of prion rods or plaques on electron micrographs of prepared brain material.
History of Diagnosis
• Kuru, the most well-known prion disease, is characterized by tremors (the word "kuru" means "shivering"), ataxia, and dementia.
• Up to 50 years may pass before the condition manifests itself.
• The majority of CJD patients experience myoclonus, pyramidal tract dysfunction, and rapidly advancing dementia early in the disease.
• Cognitive slowness, concentration issues, poor judgment, and memory loss are all signs of mental disability.
• Visual or other kinds of hallucinations may coexist with mood swings and emotional instability. • Cortical, subcortical, cerebellar, and spinal cord abnormalities can occur in nearly any combination. A more than 90% of patients develop myoclonus. Other motor symptoms and indicators may include choreoathetosis, clumsiness, and tremor.
• Approximately two-thirds of patients experience a parkinsonian extrapyramidal condition as the illness worsens, with
stiffness and hypokinesia. About half of patients experience extensor plantar reactions, hyperreflexia, and spasticity.
• In prion disease forms such fatal familial insomnia, autonomic (hyperthermia, hypertension, tachycardia) and endocrine (hypercortisol, growth hormone) problems may be observed.
• Patients with vCJD range in age from 19 to 41 years and have a progressive condition that leads to death between 7–23 months after beginning. • New cases of CJD have recently been reported in some European nations (mostly the United Kingdom) as a result of BSE transmission. Ataxia and early, noticeable behavioral abnormalities are among the clinical characteristics. Most people develop progressive dementia and myoclonus as later symptoms.
MEDICAL EXAMINATION
• Cognitive decline is prevalent and includes behavioral disorders, dementia, memory loss, and sleeplessness.
• More than 90% of patients have myoclonus.
• There may be cerebellar symptoms like ataxia and nystagmus.
• Up to 80% of patients may experience spasticity, hyperreflexia, and a positive Babinski sign.
Tests for Diagnosis and Interpretation Lab
• Only a brain histology investigation may provide a definitive diagnosis for all types of CJD.
• A comprehensive search for alternative processes should be initiated if cerebrospinal fluid (CSF) pleocytosis is atypical.
The sensitivity and specificity of 14-3-3, an aberrant protein, range from 60% to 90%, however it has been connected to CJD.
• Herpes, Alzheimer's disease, vascular dementia, and paraneoplastic syndromes are among the other illnesses that can potentially result in 14-3-3 increases.
• There is no doubt that mutations in the PRNP gene are linked to family occurrences of CJD, according to recent molecular genetic research. Variations in the disease's clinical phenotype within specific familial clusters may be related to a number of mutations that have been identified. Point mutations at codons 178, 200, and 210 are among them. Several CJD families also have octrepeat insertion in the PRNP gene.
• The brain-specific S 100 protein's median serum concentration is greater in CJD patients than in controls.
• The normal periodic EEG pattern typically linked to CJD is absent in vCJD.
Laboratory testing are useful in ruling out alternative causes of fast developing dementia. Prion protein plaques are widely dispersed throughout the cerebrum and cerebellum.
• Although the protein level may be slightly higher, the CSF is usually unremarkable.
• A quick diagnostic method called extraneural prion protein testing is being developed.
Imagining
• The amount of tissue loss observed on CT and MRI typically appears to be out of proportion to the severity of clinical dementia. Areas of elevated T2 signal intensity in the striatum have been seen on MRI in certain cases.
• Single-photon emission computed tomography (SPECT) examination of vCJD illness revealed decreased brain cortical perfusion.
Diagnostic Techniques and Other
• In some types, such sCJD, where sensitivity is 64% and specificity is 91%, the EEG can be a helpful diagnostic tool.
• Bilaterally synchronized sharp-wave complexes that occur at intervals of 0.5 to 2.5 will alternate with a generalized slow background to form a predicted pattern of CJD.
s and extending for 100–600 ms. • This typical EEG pattern is present in roughly 60–95% of patients, albeit it could not be seen at an early or advanced stage of the illness.
• Sharp-wave complexes may not be evident in Kuru, fatal familial insomnia, variant, or familial CJD.
Pathological Results
Small vacuoles occur inside the neuropil, giving it the distinctive spongiform look; multicentric plaques with spicules (cerebellum, mid-brain, and cerebrum) that stain for aberrant prion gene protein products, PrPSc, are PAS-positive.
DISTINCTIVE DIAGNOSIS
Alzheimer's disease, frontotemporal dementia, Lewy body dementia, alcoholism, HIV, tubercular meningitis, neurosyphilis, Whipple's disease, progressive multifocal leukoencephalopathy, lymphoma, amyloid angiopathy, metabolic abnormalities, and autoimmune disorders are among the many conditions that can also exhibit myoclonus and dementia symptoms.
MEDICATION FOR TREATMENT
• There is no specific treatment for CJD, and it is always deadly.
• In a few anecdotal case reports, amantadine has been shown to halt the advancement of the disease; however, the effects have not been repeatable.
• Other medications, including PrPSc inhibitors (chlorpromazine) and cytoprotective medicines (flupirtine), have been explored with little to no success in survival.
• Research is being done on molecular targeting and immunotherapy.
OTHER PROCEDURES AND SURGERY
For tissue diagnosis, neurosurgical services must be consulted. The high suspicion of prion disease should be communicated to all services, including pathology.
Continuing Care Follow-Up Suggestions
Sequential examinations conducted at biweekly or monthly intervals may reveal ventricular enlargement and quickly increasing brain tissue loss in certain patients.
Since there are now no treatments for PROGNOSIS disease, it is typically fatal.
0 Comments
